. Poizot-martin, Marseille Sainte Marguerite); C

H. Mokhtari, C. Tissot-dupont, L. Toméi, A. Y. Meddeb, and I. Belkhir, Ravaux (Marseille, pô le de maladies infectieuses)

C. Delaugerre, J. Ghosn, and J. Lacombe, Significant Reduction in HIV Virologic Failure During a 15-Year Period in a Setting With Free Healthcare Access, Clinical Infectious Diseases, vol.25, issue.8, pp.463-72, 2015.
DOI : 10.1056/NEJMoa0708975

J. Lennox, E. Dejesus, and D. Berger, Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1???Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.55, issue.1, pp.39-48, 2010.
DOI : 10.1097/QAI.0b013e3181da1287

URL : http://pdfs.journals.lww.com/jaids/2010/09010/Raltegravir_Versus_Efavirenz_Regimens_in.5.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1507211513795;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzd0iJv6m0ZkAgdHv8yEv9Bul7VMBR6hStE6VImklz779c=;hash|+ZKcMZnxBdvxlIgpyt2low==

J. Rockstroh, E. Dejesus, and K. Henry, A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.62, issue.5, pp.483-489, 2013.
DOI : 10.1097/QAI.0b013e318286415c

J. Lennox, R. Landovitz, and H. Ribaudo, Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor???Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1, Annals of Internal Medicine, vol.161, issue.7, pp.461-71, 2014.
DOI : 10.7326/M14-1084

A. Phillips, S. Staszewski, and R. Weber, HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load, JAMA, vol.286, issue.20, pp.2560-2567, 2001.
DOI : 10.1001/jama.286.20.2560

URL : http://jama.jamanetwork.com/data/journals/jama/4809/joc02184.pdf

P. Pugliese, L. Cuzin, and A. Cabie, A large French prospective cohort of HIV-infected patients: the Nadis Cohort, HIV Medicine, vol.10, issue.8, pp.504-515, 2009.
DOI : 10.1111/j.1468-1293.2009.00719.x

P. Rosenbaum, The central role of the propensity score in observational studies for causal effects, Biometrika, vol.70, issue.1, pp.41-55, 1983.
DOI : 10.1093/biomet/70.1.41

F. Raffi, A. Rachlis, and C. Brinson, Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials, AIDS, vol.29, issue.2, pp.167-74, 2015.
DOI : 10.1097/QAD.0000000000000519

H. Günthard, M. Saag, and C. Benson, Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults, JAMA, vol.316, issue.2, pp.191-210, 2016.
DOI : 10.1001/jama.2016.8900

R. Paredes, A. Mocroft, and O. Kirk, Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe, Archives of Internal Medicine, vol.160, issue.8, pp.1123-1155, 2000.
DOI : 10.1001/archinte.160.8.1123

V. Cambiano, F. Lampe, and A. Rodger, Long-term trends in adherence to antiretroviral therapy from start of HAART Younger age predicts failure to achieve viral suppression and virologic rebound among HIV-1-infected persons in serodiscordant partnerships, AIDS AIDS Res Hum Retroviruses, vol.24, issue.32, pp.1153-62, 2010.

A. European and . Society, Guidelines for Treatment of HIV-Infected Adults in Europe. Version 8.0, 2016.

A. Geretti, C. Smith, and A. Haberl, Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy, Antivir Ther, vol.13, pp.927-963, 2008.

C. Laprise, A. De-pokomandy, and J. Baril, Virologic Failure Following Persistent Low-level Viremia in a Cohort of HIV-Positive Patients: Results From 12 Years of Observation, Clinical Infectious Diseases, vol.58, issue.5, pp.1489-96, 2013.
DOI : 10.1097/QAI.0b013e3182364513

M. Vandenhende, S. Ingle, and M. May, Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients, AIDS, vol.29, pp.373-83, 2015.

G. Leierer, K. Grabmeier-pfistershammer, and A. Steuer, A single quantifiable viral load is predictive of virological failure in human immunodeficiency virus (HIV)-infected patients on combination antiretroviral therapy: the Austrian HIV Cohort Study Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load, RNA copies/mL at baseline, pp.50-51, 2012.

R. Gupta, A. Hill, and A. Sawyer, Emergence of Drug Resistance in HIV Type 1???Infected Patients after Receipt of First???Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials, Clinical Infectious Diseases, vol.47, issue.5, pp.712-734, 2008.
DOI : 10.1097/QAI.0b013e31814278c0

I. Malet, S. Fourati, M. , and L. , Risk factors for raltegravir resistance development in clinical practice, Journal of Antimicrobial Chemotherapy, vol.5, issue.5, pp.2494-500, 2012.
DOI : 10.1186/1742-4690-5-74

URL : https://academic.oup.com/jac/article-pdf/67/10/2494/2159237/dks254.pdf

V. 25-avettand-fènoël, L. Hocqueloux, and J. Ghosn, SUMMARY, Clinical Microbiology Reviews, vol.29, issue.4, pp.859-80, 2016.
DOI : 10.1128/CMR.00015-16

J. Li and D. Kuritzkes, Clinical Implications of HIV-1 Minority Variants, Clinical Infectious Diseases, vol.51, issue.11, pp.1667-74, 2013.
DOI : 10.1128/JCM.02652-12